NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease, announced the approval of inducement share options for eleven new non-executive employees. The grants, totaling 197,000 of NewAmsterdam's ordinary shares, are part of the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $20.03, reflecting the closing market price as of May 1, 2025. The vesting schedule includes 25% of the shares vesting on the one-year anniversary of the vesting commencement date, with the remainder vesting over the following 36 months, contingent on continued service with the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。